The Pancreatic Cancer Action Network Announces Appointments to Scientific Advisory Board
Aug 13 13
The Pancreatic Cancer Action Network to welcome three new members to its prestigious Scientific Advisory Board: Sunil Hingorani, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA; Kimberly Kelly, PhD, University of Virginia, Charlottesville, VA; and Steven Leach, MD, Johns Hopkins University, Baltimore, MD. Vincent Picozzi, MD, Virginia Mason Medical Center, Seattle, WA, was appointed chair of the organization's Medical Advisory Board. Dr. Hingorani played a lead role in the development of the first genetically engineered mouse model of pancreatic cancer that accurately recapitulates the human disease. Dr. Kelly's work focuses on imaging techniques to improve early detection and diagnosis of pancreatic cancer. Based on findings funded by organization, Dr. Kelly has cofounded a biotechnology company and is currently conducting an early-phase clinical trial to test her noninvasive early detection biomarker. Dr. Leach looks at the early development of the normal pancreas to provide clues to how tumors arise. He also studies the earliest stages of pancreatic cancer initiation to discover better methods to detect and treat the disease before it has progressed to become more aggressive. Dr. Picozzi has been the principal investigator on a number of other clinical trials in pancreatic cancer. Dr. Picozzi joined the Pancreatic Cancer Action Network's Medical Advisory Board in 2008.
The Pancreatic Cancer Action Network Announces Executive Changes
Jul 9 13
The Pancreatic Cancer Action Network announced Laurie MacCaskill has been appointed Chair of the National Board of Directors of the organization, effective July 1. MacCaskill is the first pancreatic cancer patient to hold this position. The organization has also appointed Jeanne Ruesch to Vice Chair effective July 1. Ruesch serves on the board in honor of her late husband, Otto J. Ruesch.